Wahl, Bryan. M.D.

Bryan Wahl is a physician, attorney, and pharmaceutical executive, serving as the General Counsel at Tarsus Pharmaceuticals (NASDAQ: TARS) since January 2021 and leading the Legal, Compliance, and Innovation teams. Tarsus has launched the first and only FDA approved treatment for Demodex blepharitis. Bryan is board-certified in internal medicine and also continues to practice medicine as a hospitalist physician since 2002, taking care of patients on the wards and in the ICU. 

Prior to joining Tarsus, Bryan was a Partner at Knobbe Martens LLP, where he focused on intellectual property protection, infringement studies and due diligence for financings and strategic transactions, specifically with respect to pharmaceutical, biotechnology and medical device companies. Bryan counseled clients from the pre-Series A stage through exit, including Tarsus, which has been one of his clients since shortly after it was founded. 

Prior to joining Knobbe Martens, Bryan entered medical school after one undergraduate year, and received his medical degree with honors from the University of Hawaii John A. Burns School of Medicine in 1999. He completed an internal medicine residency in the UCLA-affiliated Cedars-Sinai Medical Center program in Los Angeles in 2002, and is board certified in Internal Medicine. Bryan earned his law degree from the University of California, Berkeley School of Law in 2005. In law school, he received three American Jurisprudence Awards, two Prosser Awards, and the Barbee Fellowship, researching conflicts of interest of hospital institutional review boards, and was a summer extern for the Honorable Ronald T.Y. Moon, Chief Justice of the Hawaii Supreme Court.